hims semaglutide california A & Hers commercial promoting compounded weight loss drugs in this year’s Super Bowl is spurring concerns from industry watchers over how the FDA regulates the gray area of advertising copycat Hims & Hers Plan to

The global GLP-1 market, estimated at $53.46 billion in 2024 and projected to reach $156.71 billion by 2030, is largely controlled by Novo Nordisk and Eli Lilly, holding over 80% of the market

Brand-name GLP-1 medications list at $1,000+ per month at pharmacy retail, though the manufacturers now sell direct for far less: Wegovy runs $199$399 per month through NovoCare Pharmacy and Zepbound $299$449 per month through LillyDirect

Ethics declarations Competing interests J.L

These drugs are not recommended for people with severe kidney issues or end-stage kidney disease

And help change the narrative and help us all get past our preconceived biases about ketosis and help us realize that we can and should do much better than simply telling our patients to eat better and leave it at that